An oncologist’s nightmare: “As of today, we no longer have any supply of carboplatin.”

FDA debuts precheck manufacturing program to boost domestic drug development

FDA has launched a venture in onshoring domestic drug development called the Precheck Pilot Program.

February 06, 2026

NCCN updates guidelines recognizing MammaPrint to guide personalized anthracycline use in HR+/HER2- early‑stage breast cancer

The NCCN added MammaPrint + BluePrint to the Clinical Practice Guidelines in Oncology for the identification of a subset of hormone receptor positive, HER2-negative early-stage breast cancer patients most likely to benefit from anthracycline-based chemotherapy.

February 06, 2026

Vol.52 No.05

Drugs & Targets

FDA issues a boxed warning for capecitabine and fluorouracil on risks associated with DPD deficiency

FDA announced recent updates to the product labeling of capecitabine (Xeloda) and fluorouracil (5-FU) related to risks associated with dihydropyrimidine dehydrogenase deficiency.

February 06, 2026

Vol.52 No.05

Cancer Policy

FDA delays drug reviews in new voucher program amid safety, efficacy concerns

The reviews of two drugs granted priority review via FDA’s new priority voucher program, Commissioner’s National Priority Voucher (CNPV) Pilot Program, have been delayed.

January 30, 2026

Vol.52 No.04

By Claire Marie Porter

Drugs & Targets

FDA approves Darzalex Faspro as quad regimen for all newly diagnosed MM

FDA has approved Darzalez Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. D-VRd is the only anti-CD38 antibody-based regimen with approved indications across newly diagnosed patients, regardless of transplant eligibility.

January 30, 2026

Vol.52 No.04

Drugs & Targets

Trodelvy added to NCCN guidelines as preferred regimen option for first-line metastatic TNBC

Trodelvy (sacituzumab govitecan-hziy) was added to the NCCN Guidelines as a category 1 preferred first-line treatment option for people with metastatic triple-negative breast cancer whose disease is PD-L1 negative (CPS <10) and no germline BRCA1/2 PV.

January 30, 2026

Vol.52 No.04

An oncologist’s nightmare: “As of today, we no longer have any supply of carboplatin.”

YOU MAY BE INTERESTED IN

FDA debuts precheck manufacturing program to boost domestic drug development

NCCN updates guidelines recognizing MammaPrint to guide personalized anthracycline use in HR+/HER2- early‑stage breast cancer

FDA issues a boxed warning for capecitabine and fluorouracil on risks associated with DPD deficiency

FDA delays drug reviews in new voucher program amid safety, efficacy concerns

FDA approves Darzalex Faspro as quad regimen for all newly diagnosed MM

Trodelvy added to NCCN guidelines as preferred regimen option for first-line metastatic TNBC

Renew today!

Subscriber content

Never miss an issue!

Login